ArticleApplied and environmental microbiology2011
Use of RmInt1, a group IIB intron lacking the intron-encoded protein endonuclease domain, in gene targeting.
Article in Applied and environmental microbiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Identification of Group II Intron RmInt1 Binding Sites in a Bacterial Genome.Frontiers in molecular biosciences · 2022Article
- Visualizing group II intron dynamics between the first and second steps of splicing.Nature communications · 2020Article
- Localization of a bacterial group II intron-encoded protein in human cells.Scientific reports · 2015Article
- Visualizing the ai5γ group IIB intron.Nucleic acids research · 2014Article
- Biotechnological applications of mobile group II introns and their reverse transcriptases: gene targeting, RNA-seq, and non-coding RNA analysis.Mobile DNA · 2014Article
- Insights into the strategies used by related group II introns to adapt successfully for the colonisation of a bacterial genome.RNA biology · 2014Review
- Use of the computer-retargeted group II intron RmInt1 of Sinorhizobium meliloti for gene targeting.RNA biology · 2014Article
- Now on display: a gallery of group II intron structures at different stages of catalysis.Mobile DNA · 2013Article
- A targetron system for gene targeting in thermophiles and its application in Clostridium thermocellum.PloS one · 2013Article
- Independent activity of the homologous small regulatory RNAs AbcR1 and AbcR2 in the legume symbiont Sinorhizobium meliloti.PloS one · 2013Article
- The brown algae Pl.LSU/2 group II intron-encoded protein has functional reverse transcriptase and maturase activities.PloS one · 2013Article
- Article
- Article
- Exon sequence requirements for excision in vivo of the bacterial group II intron RmInt1.BMC molecular biology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The group IIA intron Ll.LtrB from Lactococcus lactis and the group IIB intron EcI5 from Escherichia coli have intron-encoded proteins (IEP) with a DNA-binding domain (D) and an endonuclease domain (En). Both have been successfully retargeted to invade target DNAs other than their wild-type target sites. RmInt1, a subclass IIB3/D intron with an IEP lacking D and En domains, is highly active in retrohoming in its host, Sinorhizobium meliloti. We found that RmInt1 was also mobile in E. coli and that retrohoming in this heterologous host depended on temperature, being more efficient at 28°C than at 37°C. Furthermore, we programmed RmInt1 to recognize target sites other than its wild-type site. These retargeted introns efficiently and specifically retrohome into a recipient plasmid target site or a target site present as a single copy in the chromosome, generating a mutation in the targeted gene. Our results extend the range of group II introns available for gene targeting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.